Effects of Psilocybin in Major Depressive Disorder
Sponsor: Johns Hopkins University
Listed as NCT03181529, this PHASE2 trial focuses on Major Depressive Disorder and remains completed. Sponsored by Johns Hopkins University, it has been updated 10 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jan 2022 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 5 earlier versions
-
Jun 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2018 — Jun 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Sep 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Johns Hopkins University
For direct contact, visit the study record on ClinicalTrials.gov .